Stock Performance and Market Context
On 17 Dec 2025, Mankind Pharma's stock price touched Rs.2100.1, the lowest level recorded in the past year. This decline comes after two consecutive days of falling prices, although the stock showed some recovery today by gaining marginally. Despite this uptick, the share price remains below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating sustained downward momentum over multiple time frames.
In comparison, the broader market index, Sensex, experienced a volatile session. After opening 176.40 points higher, it reversed course to close 204.76 points lower at 84,651.50, a decline of 0.03%. The Sensex remains close to its 52-week high of 86,159.02, trading just 1.78% below that peak. Mid-cap stocks led the market with a slight gain of 0.01% in the BSE Mid Cap index, while Mankind Pharma, classified under the Pharmaceuticals & Biotechnology sector, underperformed relative to these broader indices.
Long-Term and Recent Returns
Over the last twelve months, Mankind Pharma's stock has recorded a return of -21.34%, contrasting with the Sensex's positive return of 4.91% over the same period. This underperformance extends beyond the one-year horizon, with the stock lagging behind the BSE500 index in the last three years, one year, and three months. The 52-week high for the stock was Rs.3050, highlighting the extent of the decline to the current low.
Financial Metrics and Profitability
The company’s financial results for the latest six months show a profit after tax (PAT) of Rs.949.83 crores, reflecting a reduction of 20.05% compared to previous periods. Interest expenses for the nine months stand at Rs.530.87 crores, representing a growth of 122.24%. Return on Capital Employed (ROCE) for the half-year is recorded at 12.33%, which is relatively modest within the sector. The stock’s valuation metrics indicate an enterprise value to capital employed ratio of 4.5 times, suggesting a valuation that aligns fairly with peer averages historically.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
Valuation and Efficiency Considerations
Mankind Pharma’s ROCE of 11.7% indicates a moderate level of capital efficiency, while the company’s management efficiency is highlighted by a higher ROCE figure of 25.78% in other assessments. The company’s ability to service debt is supported by a low Debt to EBITDA ratio of 0.54 times, reflecting manageable leverage levels relative to earnings before interest, taxes, depreciation, and amortisation.
Despite the stock’s recent price decline, its valuation remains in line with historical averages of its peers, suggesting that the market is pricing in the current financial performance and sector conditions. The stock’s performance over the past year, with a profit contraction of 17.2%, has contributed to the subdued market sentiment.
Institutional Holdings and Market Position
Mankind Pharma has institutional holdings of 24.76%, indicating a significant presence of investors with substantial resources and analytical capabilities. This level of institutional ownership often reflects a degree of confidence in the company’s fundamentals, even as the stock price experiences downward pressure.
Mankind Pharma or something better? Our SwitchER feature analyzes this large-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Sector and Industry Overview
Mankind Pharma operates within the Pharmaceuticals & Biotechnology sector, which has experienced mixed performance in recent sessions. While the Sensex and mid-cap indices have shown resilience, individual stocks such as Mankind Pharma have faced headwinds. The sector’s dynamics, including regulatory factors, competitive pressures, and evolving market conditions, continue to influence stock valuations and investor sentiment.
Summary of Current Position
The stock’s fall to Rs.2100.1 marks a notable point in its price trajectory, reflecting a combination of financial results, valuation considerations, and broader market trends. Trading below all major moving averages signals a cautious stance among market participants. The company’s financial indicators, including profit contraction and interest expense growth, contribute to the current market assessment. However, the presence of strong management efficiency and low leverage provides a balanced view of the company’s operational standing.
Conclusion
Mankind Pharma’s stock reaching a 52-week low underscores the challenges faced in maintaining price levels amid sector fluctuations and company-specific financial developments. The stock’s performance relative to the Sensex and sector indices highlights the divergence in market outcomes within the pharmaceutical space. Investors and market observers will continue to monitor the stock’s movement in relation to its financial metrics and sector trends.
Only for Rs. 14,999 - Get Access to 2 Years + 6 Months of All Premium Features on MarketsMojo. As low as ₹500/month! Claim 83% OFF →
